Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 7, 2014
Previous Article Next Article

RGD-targeted MnO nanoparticles as T1 contrast agents for cancer imaging – the effect of PEG length in vivo

Author affiliations

Abstract

As magnetic resonance imaging (MRI) contrast agents, T1 Gd3+ chelates are generally the preferred option for radiologists over T2 iron oxide nanoparticles. The main reason for the popularity of T1 agents is the easier interpretation of T1-weighted MR images. However, the chemical versatility of nanoparticulate platforms makes them ideal candidates for the next generation of targeted MRI contrast agents. In this context, we present herein the design and preparation of a nanoparticulate contrast agent based on MnO, which presents T1 contrast enhancement properties as well as nanoparticle formulation. Functionalization of MnO nanoparticles with the extensively studied RGD peptide was used to target tumours over-expressing the αvβ3 integrin. PEG (polyethylene glycol) molecules were used to increase the blood half-life of the nanoparticles in vivo, and the effect of different PEG lengths on the final contrast on MR images was investigated.

Graphical abstract: RGD-targeted MnO nanoparticles as T1 contrast agents for cancer imaging – the effect of PEG length in vivo

Back to tab navigation

Supplementary files

Article information


Submitted
11 Oct 2013
Accepted
14 Nov 2013
First published
20 Dec 2013

J. Mater. Chem. B, 2014,2, 868-876
Article type
Paper

RGD-targeted MnO nanoparticles as T1 contrast agents for cancer imaging – the effect of PEG length in vivo

J. Gallo, I. S. Alam, I. Lavdas, M. Wylezinska-Arridge, E. O. Aboagye and N. J. Long, J. Mater. Chem. B, 2014, 2, 868
DOI: 10.1039/C3TB21422B

Social activity

Search articles by author

Spotlight

Advertisements